The objectives of this clinical study are as follows(ARDS caused by pneumonia cohort):~Primary objective To investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonia~Secondary objective To confirm the safety of HLCM05 in patients with ARDS caused by pneumonia~Exploratory objective To investigate changes of biomarkers in patients with ARDS caused by pneumonia~The number of patients enrolled is 30 (20 patient in the HLCM051 group and 10 patients in the standard therapy group)~The objectives of this clinical study is as follows(ARDS caused by COVID-19 cohort):~1. Exploratory objective To investigate the safety and the efficacy of HLCM051 in patients with ARDS caused by SARS-Cov-2 infection~The number of patients enrolled is Approximately 5 (the HLCM051 group only)
The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.